Literature DB >> 6372026

Role of anaerobic bacteria in bite-wound infections.

E J Goldstein, D M Citron, S M Finegold.   

Abstract

The etiologic agents usually involved in wound infections due to human or animal bites are the aerobic skin flora of the victim, e.g., Staphylococcus aureus, and/or the aerobic oral flora of the biter, e.g., Pasteurella multocida. While anaerobic bacteria are predominant in the normal oral flora of humans and animals, their importance in the pathogenesis of bite-wound infections has not been stressed. Most investigators in this field have either not cultured these wounds for anaerobic bacteria or not utilized optimal culture techniques. In a series of studies on human and animal bite wounds, methods that are optimal for recovery of anaerobic bacteria were used. Anaerobes were found in significant quantities in 39% of animal bite wounds, 50% of human bite wounds, and 56% of clenched-fist injuries. Several species of anaerobes usually were present in the wounds and always were present in mixed culture with aerobic oral flora. The anaerobes most commonly isolated included Bacteroides asaccharolyticus, Bacteroides bivius, Bacteroides disiens, Bacteroides melaninogenicus, Bacteroides oralis, Bacteroides ruminicola, Bacteroides pneumosintes, Bacteroides ureolyticus, Fusobacterium nucleatum, Fusobacterium russii, Peptococcus species, Peptostreptococcus species, and Veillonella species. Initial, empiric antimicrobial therapy for bite wounds should be directed against potential anaerobic as well as aerobic pathogens.

Entities:  

Mesh:

Year:  1984        PMID: 6372026     DOI: 10.1093/clinids/6.supplement_1.s177

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  13 in total

1.  Bacteremia with Bacteroides pyogenes after a cat bite.

Authors:  Ida Ringsborg Madsen; Ulrik Stenz Justesen
Journal:  J Clin Microbiol       Date:  2011-06-01       Impact factor: 5.948

2.  Susceptibility of bite wound bacteria to seven oral antimicrobial agents, including RU-985, a new erythromycin: considerations in choosing empiric therapy.

Authors:  E J Goldstein; D M Citron; A E Vagvolgyi; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

3.  Comparative activities of cefuroxime, amoxicillin-clavulanic acid, ciprofloxacin, enoxacin, and ofloxacin against aerobic and anaerobic bacteria isolated from bite wounds.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

4.  Bacterial diversity in human subgingival plaque.

Authors:  B J Paster; S K Boches; J L Galvin; R E Ericson; C N Lau; V A Levanos; A Sahasrabudhe; F E Dewhirst
Journal:  J Bacteriol       Date:  2001-06       Impact factor: 3.490

5.  In vitro activities of cefcanel and some other cephalosporins against Pasteurella multocida.

Authors:  E Holst; J Rollof; H Miörner
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

6.  Prevention of post-operative infections after surgical treatment of bite wounds.

Authors:  Axel Kramer; Ojan Assadian; Matthias Frank; Claudia Bender; Peter Hinz
Journal:  GMS Krankenhhyg Interdiszip       Date:  2010-09-21

7.  Management of human and animal bite wound infection: an overview.

Authors:  Itzhak Brook
Journal:  Curr Infect Dis Rep       Date:  2009-09       Impact factor: 3.725

8.  Antimicrobial susceptibilities and clinical sources of Dialister species.

Authors:  F Morio; H Jean-Pierre; L Dubreuil; E Jumas-Bilak; L Calvet; G Mercier; R Devine; H Marchandin
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

9.  Propionibacterium acnes osteomyelitis: case report and review of the literature.

Authors:  R C Noble; S B Overman
Journal:  J Clin Microbiol       Date:  1987-02       Impact factor: 5.948

10.  Dialister pneumosintes associated with human brain abscesses.

Authors:  J M Rousée; D Bermond; Y Piémont; C Tournoud; R Heller; P Kehrli; M L Harlay; H Monteil; B Jaulhac
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.